Pipeline Overview

We are developing a pipeline of purpose-built, targeted medicines against genomic drivers of cancer. By designing and developing highly selective medicines, we have the potential to deliver treatments that increase clinical benefit in genomically defined patient populations and fulfill the promise of precision medicine for appropriate patients.

Early Stage Clinical Development
Late Stage Clinical Development
Regulatory Submission
VITRAKVI® (larotrectinib) - TRK Inhibitor
LOXO-292 - Cancers Harboring RET Fusions or Activating RET Mutations
LOXO-195 - Second Generation TRK Inhibitor for Potential Acquired Resistance
LOXO-305 - Non-Covalent BTK Inhibitor for B-cell Cancers
Second Generation RET Inhibitor for Potential Acquired Resistance
FGFR Program - Cancers Harboring Alterations of Fibroblast Growth Factor Receptor (FGFR)

* Marketing Authorization Application submitted by Bayer.

** Co-promotion between Loxo Oncology and Bayer.